Breast Surgery Ward, Department of Oncology, First Affiliated Hospital of China Medical University, Heping, 110001, Shenyang, Liaoning Province, China.
Med Oncol. 2010 Sep;27(3):747-52. doi: 10.1007/s12032-009-9279-8. Epub 2009 Aug 6.
The aim of the study is to investigate the alterations in expression of estrogen receptor alpha (ER), progesterone receptor (PgR), c-erbB2 gene (HER-2/neu), and P53 protein in the progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinomas (IDC), and the association between their expression and clinicopathologic findings. The mastectomy specimens of 520 cases containing both DCIS and IDC were examined. The expression of ER, PgR, HER-2/neu, and P53 proteins were examined by immunohistochemistry. Linear regression was used to investigate the correlation among ER, PgR, HER-2/neu, P53 protein expression, and the clinicopathologic factors. There was a significant decrease of ER and PgR expression in IDC compared to DCIS (32.81 vs. 21.05%, chi(2) = 4.45, P = 0.035; 26.56 vs. 15.57%, chi(2) = 4.82, P = 0.028, respectively). In contrast, there was a significant increase of HER-2/neu expression in IDC compared to DCIS (10.94 vs. 21.27%, chi(2) = 3.88, P = 0.049). However, there was no significant difference in expression of p53 between DCIS and IDC. In both DCIS and IDC, a significant positive correlation was observed between ER and PgR receptor expression (r = 0.67, P = 0.00; r = 0.56, P = 0.00, respectively). In conclusion, these findings substantiate the notion that breast cancer progression is often associated with alterations in expressions of ER, PgR, and HER-2/neu. The underlying mechanisms of these alterations need further investigation.
本研究旨在探讨从导管原位癌（DCIS）到浸润性导管癌（IDC）的过程中，雌激素受体α（ER）、孕激素受体（PgR）、c-erbB2 基因（HER-2/neu）和 P53 蛋白表达的变化及其与临床病理特征的关系。对 520 例包含 DCIS 和 IDC 的乳房切除术标本进行了研究。采用免疫组织化学法检测 ER、PgR、HER-2/neu 和 P53 蛋白的表达。采用线性回归分析 ER、PgR、HER-2/neu、P53 蛋白表达与临床病理因素的相关性。与 DCIS 相比，IDC 中 ER 和 PgR 的表达明显降低（32.81%比 21.05%，χ^2^=4.45，P=0.035；26.56%比 15.57%，χ^2^=4.82，P=0.028）。相反，与 DCIS 相比，IDC 中 HER-2/neu 的表达明显增加（10.94%比 21.27%，χ^2^=3.88，P=0.049）。然而，DCIS 和 IDC 中 P53 的表达无显著差异。在 DCIS 和 IDC 中，ER 和 PgR 受体表达之间均存在显著的正相关（r=0.67，P=0.00；r=0.56，P=0.00）。总之，这些发现证实了乳腺癌的进展通常与 ER、PgR 和 HER-2/neu 表达的改变有关。这些改变的潜在机制需要进一步研究。
